Basel, Switzerland, April 01, 2021 
 
   Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced the successful 
closing of the previously announced divestment of its Chinese research 
and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. 
("BPC") to the U.S.-based custom manufacturing organization PHT 
International Inc. ("PHT") for a total consideration of USD 6.3 million. 
Basilea has received the initial payment of USD 2.5 million and is 
entitled to receive additional payments of USD 3.8 million over the 
course of the next three years. All 72 employees of BPC and the 
facilities have been transferred to PHT. PHT continues to provide R&D 
services to Basilea through the existing site in China. 
 
   About Basilea 
 
   Basilea is a commercial-stage biopharmaceutical company founded in 2000 
and headquartered in Switzerland. We are committed to discovering, 
developing and commercializing innovative drugs to meet the medical 
needs of patients with cancer and infectious diseases. We have 
successfully launched two hospital brands, Cresemba for the treatment of 
invasive fungal infections and Zevtera for the treatment of severe 
bacterial infections. We are conducting clinical studies with two 
targeted drug candidates for the treatment of a range of cancers and 
have a number of preclinical assets in both cancer and infectious 
diseases in our portfolio. Basilea is listed on the SIX Swiss Exchange 
(SIX: BSLN). Please visit basilea.com 
https://www.globenewswire.com/Tracker?data=89IIgLOooliUJuJrMHKuBAVhLpb29zDwsMz3siUeqjEf25Od2Ow3RiJzJOw_oJLhJq3OnMzD3OsBFRlpr7B7Lg== 
. 
 
   Disclaimer 
 
   This communication expressly or implicitly contains certain 
forward-looking statements, such as "believe", "assume", "expect", 
"forecast", "project", "may", "could", "might", "will" or similar 
expressions concerning Basilea Pharmaceutica Ltd. and its business, 
including with respect to the progress, timing and completion of 
research, development and clinical studies for product candidates. Such 
statements involve certain known and unknown risks, uncertainties and 
other factors, which could cause the actual results, financial condition, 
performance or achievements of Basilea Pharmaceutica Ltd. to be 
materially different from any future results, performance or 
achievements expressed or implied by such forward-looking statements. 
Basilea Pharmaceutica Ltd. is providing this communication as of this 
date and does not undertake to update any forward-looking statements 
contained herein as a result of new information, future events or 
otherwise. 
 
   For further information, please contact: 
 
 
 
 
  Peer Nils Schröder, PhD 
   Head of Corporate Communications & Investor Relations 
  Phone                                     +41 61 606 1102 
  E-mail        media_relations@basilea.com 
                 investor_relations@basilea.com 
 
 
   This press release can be downloaded from www.basilea.com. 
 
   Attachment 
 
 
   -- Press release (PDF) 
      https://ml-eu.globenewswire.com/Resource/Download/3b086587-95de-47b6-82c9-7c9de4f82c83

(END) Dow Jones Newswires

April 01, 2021 01:25 ET (05:25 GMT)